Literature DB >> 10977801

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

G L Bakris, M Williams, L Dworkin, W J Elliott, M Epstein, R Toto, K Tuttle, J Douglas, W Hsueh, J Sowers.   

Abstract

Over 11 million Americans have both diabetes and hypertension-comorbid diseases that strongly predispose people to both renal as well as cardiovascular (CV) injury. Hypertension substantially contributes to CV morbidity and mortality in people with diabetes. Diabetes is the most common cause of end-stage renal disease in the United States. Furthermore, hypertension and diabetes are particularly prevalent in certain populations, such as African-Americans and Native Americans. Since the 1994 Working Group Report on Hypertension and Diabetes, a large body of clinical trial data has affirmed the original blood pressure goal of less than 130/85 mmHg recommended to preserve renal function and reduce CV events in people with hypertension and diabetes. Data that are more recent have emerged, however, to support an even lower diastolic blood pressure goal, ie, 80 mmHg, in order to optimally preserve renal function and reduce CV events in people with diabetic nephropathy. A review of clinical trials indicates that more than 65% of people with diabetes and hypertension will require two or more different antihypertensive medications to achieve the new suggested target blood pressure of 130/80 mmHg. The purpose of this report is to update the previous recommendations with a focus on level of blood pressure control, proteinuria reduction, and therapeutic approaches to achieve these goals. We provide an evidence-based approach, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events. This report also addresses socioeconomic and cultural barriers that hinder achievement of blood pressure goals. Lastly, the report discusses approaches to resolve cultural barriers, both physician- and patient-derived, that interfere with achievement of lower blood pressure goals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10977801     DOI: 10.1053/ajkd.2000.16225

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  294 in total

Review 1.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 2.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 3.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease.

Authors:  Caroline Stigant; Lesley Stevens; Adeera Levin
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

Review 4.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 5.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 6.  Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

Authors:  George L Bakris; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 7.  The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Authors:  Kambiz Kalantarinia; Helmy M Siragy
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 8.  Role of ACE inhibitors in treating hypertensive diabetic patients.

Authors:  Dmitri Kirpichnikov; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 9.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 10.  Combating diabetic nephropathy with drug therapy.

Authors:  D Martins; K Norris
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.